Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE.

Please login or register to bookmark this article
Bookmark this %label%

To evaluate the impact of upadacitinib vs placebo and adalimumab treatment, on patient-reported outcomes (PROs) in SELECT-COMPARE in an active RA population with inadequate responses to methotrexate (MTX-IR).PROs in patients receiving upadacitinib (15 mg QD), placebo, or adalimumab (40 mg EOW) while on background MTX were evaluated over 48 weeks. PROs included PtGA and pain by VAS, HAQ-DI, 36-Item Short Form Survey (SF-36), morning (AM) stiffness duration and severity, FACIT-F, and work instability. Least squares mean (LSM) changes and proportions of patients reporting improvements ≥ minimal clinically important differences (MCID) and scores ≥ normative values were evaluated.Upadacitinib and adalimumab resulted in greater LSM changes from baseline vs placebo across all PROs (p 

View the full article @ Rheumatology (Oxford, England)
Get PDF with LibKey

Authors: Vibeke Strand, Namita Tundia, Martin Bergman, Andrew Ostor, Patrick Durez, In-Ho Song, Jeffrey Enejosa, Casey Schlacher, Yan Song, Roy Fleischmann